Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?

Author:

Anderson Evan J123ORCID,Campbell James D4,Creech C Buddy5,Frenck Robert6,Kamidani Satoshi13,Munoz Flor M78,Nachman Sharon9,Spearman Paul6ORCID

Affiliation:

1. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA

2. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

3. Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Atlanta, Georgia, USA

4. Department of Pediatrics and Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA

5. Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

6. Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio,USA

7. Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA

8. Department of Molecular Virology and Microbiology, Baylor College of Medicine  , Houston, Texas,  USA

9. Department of Pediatrics, The State University of New York (SUNY) Stony Brook; Stony Brook, New York, USA

Abstract

Abstract While adult clinical trials of coronavirus disease 2019 (COVID-19) vaccines have moved quickly into phase 3 clinical trials, clinical trials have not started in children in the United States. The direct COVID-19 impact upon children is greater than that observed for a number of other pathogens for which we now have effective pediatric vaccines. Additionally, the role of children in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission has clearly been underappreciated. Carefully conducted phase 2 clinical trials can adequately address potential COVID-19 vaccine safety concerns. Delaying phase 2 vaccine clinical trials in children will delay our recovery from COVID-19 and unnecessarily prolong its impact upon children’s education, health, and emotional well-being, and equitable access to opportunities for development and social success. Given the potential direct and indirect benefits of pediatric vaccination, implementation of phase 2 clinical trials for COVID-19 vaccines should begin now.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference53 articles.

1. SARS-CoV-2 mRNA vaccine development enabled by prototy;Corbett;bioRxiv,2020

2. A SARS-CoV-2 mRNA vaccine—preliminary report [reply];Jackson;N Engl J Med,2020

3. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report;Mulligan;medRxiv,2020

4. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial;Folegatti;Lancet,2020

5. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study;Walsh;medRxiv,2020

Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3